287 related articles for article (PubMed ID: 12211720)
1. Effect of IFN-alpha on total haemolytic activity of CH50 complement system and C3, C4 levels in children with chronic hepatitis C.
Woźniakowska-Gesicka T; Wiśniewska-Ligier M; Kupś J
Med Sci Monit; 2001 May; 7 Suppl 1():202-6. PubMed ID: 12211720
[TBL] [Abstract][Full Text] [Related]
2. Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.
El-Fatah Fahmy Hanno A; Mohiedeen KM; Deghedy A; Sayed R
Arab J Gastroenterol; 2014 Jun; 15(2):58-62. PubMed ID: 25097047
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin and complement depositions in the liver of chronic hepatitis patients.
Vasei M; Monabbati A; Alizadeh-Naeeni M; Houshmand S; Azarpira N; Lankarani KB; Mosallaee M; Taghavi Sa; Geramizadeh B; Saberi-Firouzi M; Imaniyeh MH
Hepatogastroenterology; 2008; 55(84):1066-70. PubMed ID: 18705329
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
6. Total hemolytic complement (CH50) and its fractions C3 and C4 in the sera of patients with localized juvenile periodontitis.
Anil S; Beena VT; Remani P; Mysore J; Vijayakumar T
Ann Dent; 1993; 52(1):18-20. PubMed ID: 8323245
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
8. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P; Yagüe J; Akasbi M; Bautista R; Ruano M; Claver G; Gil V; Font J
Rheumatology (Oxford); 2005 Jan; 44(1):89-94. PubMed ID: 15381790
[TBL] [Abstract][Full Text] [Related]
9. Immunology of chronic generalized periodontitis. 2. Estimation of total hemolytic complement (CH 50) and its fractions C3 and C4.
Anil S; Beena VT; Remani P; Haseenabeevi M; Vijayakumar T
Indian J Dent Res; 1991; 2(3-4):35-9. PubMed ID: 1821159
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of chronic hepatitis with interferon in children with kidney diseases].
Szczepańska M; Tobis A; Schneiberg B; Szprynger K; Kobos E; Morawiec-Knysak A
Pol Merkur Lekarski; 2005 Jan; 18(103):22-8. PubMed ID: 15859541
[TBL] [Abstract][Full Text] [Related]
11. [The assessment of the treatment of viral hepatitis C with interferon alpha in children with leukemias and lymphomas].
Pawelec K; Zielecka-Walewska B; Brojer E; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():243-6. PubMed ID: 10731976
[TBL] [Abstract][Full Text] [Related]
12. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D
Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709
[TBL] [Abstract][Full Text] [Related]
13. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
[TBL] [Abstract][Full Text] [Related]
16. [Hypocomplementaemia in children with chronic viral hepatitis as a risk factor for invasive encapsulated bacteria infection].
Pokorska-Lis M; Kowalik-Mikołajewska B; Aniszewska M
Med Wieku Rozwoj; 2008; 12(2 Pt 2):693-7. PubMed ID: 19418946
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma levels of complement in patients with acute ischemic stroke.
Cojocaru IM; Cojocaru M; Tănăsescu R; Burcin C; Atanasiu AN; Petrescu AM; Mitu AC; Iliescu I; Dumitrescu L
Rom J Intern Med; 2008; 46(1):77-80. PubMed ID: 19157274
[TBL] [Abstract][Full Text] [Related]
18. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of natural killer cells monitoring in the course of IFN-alpha therapy in children with chronic hepatitis C].
Woźniakowska-Gesicka T; Wiśniewska-Ligier M; Zeman K; Banasik M
Pol Merkur Lekarski; 2000 Jun; 8(48):376-7. PubMed ID: 10967910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
